Supernus Pharma (SUPN) Tops Q2 EPS by 3c, Revenues Miss; Offers Revised FY19 Revenues Guidance Below Consensus
Tweet Send to a Friend
Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.61, $0.03 better than the analyst estimate of $0.58. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
